Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Gains from Investment Securities (2018 - 2025)

Exagen (XGN) has disclosed Gains from Investment Securities for 8 consecutive years, with -$3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 895.92% year-over-year to -$3.9 million, compared with a TTM value of -$792000.0 through Dec 2025, down 261.63%, and an annual FY2025 reading of -$792000.0, down 261.63% over the prior year.
  • Gains from Investment Securities was -$3.9 million for Q4 2025 at Exagen, down from $2.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.4 million in Q3 2025 and bottomed at -$3.9 million in Q4 2025.
  • Average Gains from Investment Securities over 5 years is -$4631.6, with a median of $48000.0 recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 89200.0% in 2021, while the deepest fall reached 6393.33% in 2021.
  • Year by year, Gains from Investment Securities stood at -$944000.0 in 2021, then skyrocketed by 94.39% to -$53000.0 in 2022, then crashed by 126.42% to -$120000.0 in 2023, then soared by 508.33% to $490000.0 in 2024, then tumbled by 895.92% to -$3.9 million in 2025.
  • Business Quant data shows Gains from Investment Securities for XGN at -$3.9 million in Q4 2025, $2.4 million in Q3 2025, and $754000.0 in Q2 2025.